Capsida Biotherapeutics to Present New Preclinical Data for Friedreich’s Ataxia Next-Generation Gene Therapy to Target CNS, Cardiac Tissues and Sensory Regions
Industry News
News|Nov 12 2024
Global Ataxia Advocacy Organizations Unite to Host Largest International Congress for Ataxia Research in London
FARA News | Research
Blog|Nov 11 2024
Meet The Community: Aidan LeCompte
Community
News|Nov 4 2024
Webinar Recording: An Informational Webinar Hosted by Larimar Therapeutics — November 2024
FARA News | Industry News
Blog|Nov 4 2024
2024 rideATAXIA Philly and FARA & CHOP FA Symposium Recap
Events
Blog|Oct 28 2024
Meet The Community: Daniel Huber
Community
Blog|Oct 21 2024
Meet The Community: Kendall Harvey
Community
News|Oct 16 2024
Papillon Therapeutics Receives Rare Pediatric Disease Designation from the U.S. Food and Drug Administration for PPL-001 for the Treatment of Friedreich’s Ataxia
Industry News
Blog|Oct 14 2024
2024 rideATAXIA Hometown Twin Cities, MN Recap
Events
News|Oct 8 2024
PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program
Industry News
Blog|Oct 4 2024
Meet the Community 2: A Closer Look — Alijana Shakya